These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18639872)

  • 21. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of gene therapy for late neuronal ceroid lipofuscinosis.
    Sondhi D; Hackett NR; Apblett RL; Kaminsky SM; Pergolizzi RG; Crystal RG
    Arch Neurol; 2001 Nov; 58(11):1793-8. PubMed ID: 11708986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
    Bernardini F; Warburton MJ
    Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-trimester diagnosis of late-infantile neuronal ceroid lipofuscinosis (LINCL) by tripeptidyl peptidase I assay and CLN2 mutation analysis.
    Kleijer WJ; van Diggelen OP; Keulemans JL; Losekoot M; Garritsen VH; Stroink H; Majoor-Krakauer D; Franken PF; Eurlings MC; Taschner PE; Los FJ; Galjaard RJ
    Prenat Diagn; 2001 Feb; 21(2):99-101. PubMed ID: 11241534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders.
    Wisniewski KE; Kida E; Walus M; Wujek P; Kaczmarski W; Golabek AA
    Eur J Paediatr Neurol; 2001; 5 Suppl A():73-9. PubMed ID: 11589013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.
    Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS
    Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
    Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
    Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
    Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
    Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
    [No Abstract]   [Full Text] [Related]  

  • 29. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.
    Worgall S; Kekatpure MV; Heier L; Ballon D; Dyke JP; Shungu D; Mao X; Kosofsky B; Kaplitt MG; Souweidane MM; Sondhi D; Hackett NR; Hollmann C; Crystal RG
    Neurology; 2007 Aug; 69(6):521-35. PubMed ID: 17679671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late infantile neuronal ceroid lipofuscinosis is due to splicing mutations in the CLN2 gene.
    Hartikainen JM; Ju W; Wisniewski KE; Moroziewicz DN; Kaczmarski AL; McLendon L; Zhong D; Suarez CT; Brown WT; Zhong N
    Mol Genet Metab; 1999 Jun; 67(2):162-8. PubMed ID: 10356316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.
    Whiting REH; Jensen CA; Pearce JW; Gillespie LE; Bristow DE; Katz ML
    Exp Eye Res; 2016 May; 146():276-282. PubMed ID: 27039708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
    Steinfeld R; Steinke HB; Isbrandt D; Kohlschütter A; Gärtner J
    Hum Mol Genet; 2004 Oct; 13(20):2483-91. PubMed ID: 15317752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis.
    Lin L; Lobel P
    Biochem J; 2001 Jul; 357(Pt 1):49-55. PubMed ID: 11415435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis.
    Rawlings ND; Barrett AJ
    Biochim Biophys Acta; 1999 Jan; 1429(2):496-500. PubMed ID: 9989235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis.
    Ezaki J; Takeda-Ezaki M; Oda K; Kominami E
    Biochem Biophys Res Commun; 2000 Feb; 268(3):904-8. PubMed ID: 10679303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase.
    Ezaki J; Takeda-Ezaki M; Kominami E
    J Biochem; 2000 Sep; 128(3):509-16. PubMed ID: 10965052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and analysis of CLN2 variants in CHO cells: Q100R represents a polymorphism, and G389E and R447H represent loss-of-function mutations.
    Lin L; Lobel P
    Hum Mutat; 2001 Aug; 18(2):165. PubMed ID: 11462245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late-infantile neuronal ceroid lipofuscinosis (CLN2/Jansky-Bielschowsky type) in Oman.
    Koul R; Al-Futaisi A; Ganesh A; Rangnath Bushnarmuth S
    J Child Neurol; 2007 May; 22(5):555-9. PubMed ID: 17690061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.